John Vischio, MD
Rheumatology · Glastonbury, CTNPI 1417147406
Payments from drug & device makers
Across 492 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$1K
- Johnson & Johnson$959
- Mallinckrodt Hospital Products Inc.$714
- UCB, Inc.$664
- Novartis$505
- plus $3K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 146 | $2,827 |
| Amgen(2 entities) | 47 | $1,059 |
| Johnson & Johnson(2 entities) | 58 | $959 |
| Mallinckrodt Hospital Products Inc. | 15 | $714 |
| UCB, Inc. | 31 | $664 |
| Novartis | 33 | $505 |
| E.r. Squibb & Sons, L.L.C. | 23 | $418 |
| GSK | 19 | $384 |
| AstraZeneca(2 entities) | 18 | $376 |
| Pfizer | 16 | $333 |
| Sanofi | 8 | $245 |
| Kiniksa Pharmaceuticals International, PLC | 8 | $227 |
| Genentech USA, Inc. | 10 | $227 |
| Lilly USA, LLC | 8 | $191 |
| Aurinia Pharma U.S., Inc. | 7 | $165 |
| Octapharma USA, Inc. | 7 | $157 |
| ANI Pharmaceuticals, Inc. | 3 | $88 |
| Boehringer Ingelheim | 5 | $82 |
| Sandoz | 4 | $77 |
| Sobi, Inc | 3 | $76 |
| Actelion Pharmaceuticals US, Inc. | 4 | $68 |
| Fresenius Kabi USA, LLC | 2 | $62 |
| Organon | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Invivyd Inc | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $25 |
| Novo Nordisk | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Alvogen Inc | 1 | $19 |
| Endo USA, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Bioventus LLC | 1 | $12 |
| Pacira Therapeutics, Inc. | 1 | $11 |
How this compares
$10,225 in reported general payments places this provider in the 75th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Glastonbury
- Christopher ScolaGlastonbury$20K
- Ioana StanescuGlastonbury$19K
- Sandra ApentengGlastonbury$6K
- Fotios KoumpourasNorth Haven$1.5M
- Kenneth MillerDanbury$930K
- Monique HinchcliffNorth Haven$883K
- Robert SchoenGuilford$638K
- Stuart NovackNorwalk$507K
- Bret SohnStamford$460K
- Geoffrey GladsteinTrumbull$452K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.